Detalhe da pesquisa
1.
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
N Engl J Med
; 386(20): 1910-1921, 2022 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35320659
2.
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Lancet Oncol
; 22(7): 1034-1046, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34143970
3.
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers.
Curr Ther Res Clin Exp
; 93: 100604, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32963641
4.
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
Br J Cancer
; 118(2): 153-161, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28949957
5.
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
Br J Cancer
; 118(2): e3, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29361630
6.
Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design.
Future Oncol
; 14(21): 2103-2113, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29584456
7.
Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.
Vaccine
; 40(10): 1483-1492, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35131133
8.
Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + lactated ringer's solution administered subcutaneously: A phase IV, double-blind, randomized pilot study in healthy volunteers.
Curr Ther Res Clin Exp
; 70(6): 421-38, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24692835
9.
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.
Ann Intern Med
; 145(9): 660-4, 2006 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-17088579
10.
Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.
AAPS J
; 17(5): 1144-56, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25967925
11.
Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
Clin Ther
; 36(2): 211-24, 2014 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24486335
12.
Subcutaneous drug delivery: a route to increased safety, patient satisfaction, and reduced costs.
J Infus Nurs
; 35(3): 154-60, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22498485
13.
Intravenous therapy: a review of complications and economic considerations of peripheral access.
J Infus Nurs
; 35(2): 84-91, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22382792
14.
Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.
AAPS J
; 17(6): 1523-4, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26340861